Project Delivers Strong Clinical Data, IP and Prototype of Rapid Neonatal Lung Maturity Test
LONDON, Jan. 11, 2018 /PRNewswire/ -- SIME Dx, a digital molecular medicine company developing point-of-care diagnostics, has announced the completion of a 2 year EU Horizon 2020 project. The project has significantly accelerated company progress, culminating in the publication of clinical data validating a rapid Lung Maturity Test (LMT), an engineering prototype and new IP. The €2.86 million funding enabled SIME Dx to overcome technical challenges, and prepared the company for further clinical trials, regulatory approval, commercialisation and expansion into China.
A British Company has Created a Simple Test to Help Premature Babies
In December of 2016, Microsoft UK published a feature article about SIME Dx's bedside test, and the potential it had to "improve the lives of millions of premature babies ."
The feature was amongst the best-read articles of the year and, therefore, was highlighted as one of the 10 biggest UK stories of 2017.
Data for a Rapid Lung Maturity Test
Published in ACTA Paediatrica
Recently Published European Consensus Guidelines Highlight the Need for a Bedside Test
LONDON--(BUSINESS WIRE)--SIME Dx, a digital molecular medicine company developing point-of-care diagnostics, announced data validating the efficacy of a lung maturity test (LMT) in identifying infants at risk of respiratory distress syndrome (RDS) who could benefit from early surfactant treatment.